Literature DB >> 2738169

Five commercial enzyme linked immunosorbent assay kits for toxoplasma specific IgM antibody.

D H Joynson1, R A Payne, A H Balfour, E S Prestage, D G Fleck, B S Chessum.   

Abstract

Five commercially available enzyme linked immunosorbent assay (ELISA) kits for the detection of specific IgM against Toxoplasma gondii were evaluated in a three centre study and results compared with those of the Public Health Laboratory Service ELISA for Toxoplasma IgM (PHL IgM ELISA). Fifty selected sera were tested by all the methods (Toxo-M, Captia Toxo-M EIA, Toxo Enz M EIA, Toxonostika IgM EIA, Sopazyme Toxo IgM EIA) at the three reference centres in England and Wales and 177 routine sera by all the methods in one or other of the centres. Ten of the 50 selected sera contained autoimmune antibodies but no specific IgM and 29 had toxoplasma specific IgM detectable by the PHL IgM ELISA. The kits were assessed for their specificity and sensitivity compared with the PHL IgM ELISA, and the percentage coefficient of variation for binding to the solid phases was determined. They were also rated subjectively by the staff performing the assays and an overall impression of each kit was gained by allocating scores of several criteria. There was quite close agreement among the results obtained with all five commercial assays and the PHL IgM ELISA, although some of the sera pre-selected as being potentially problematic showed the limitations of some of the assays.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2738169      PMCID: PMC1141997          DOI: 10.1136/jcp.42.6.653

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  4 in total

1.  IgM antibodies in acute toxoplasmosis. II. Prevalence and significance in acquired cases.

Authors:  J S Remington; M J Miller; I Brownlee
Journal:  J Lab Clin Med       Date:  1968-05

2.  Interlaboratory evaluation of indirect enzyme-linked immunosorbent assay, antibody capture enzyme-linked immunosorbent assay, and immunoblotting for detection of immunoglobulin M antibodies to Toxoplasma gondii.

Authors:  P Herbrink; A M van Loon; J P Rotmans; F van Knapen; W C van Dijk
Journal:  J Clin Microbiol       Date:  1987-01       Impact factor: 5.948

3.  Public Health Laboratory Service enzyme linked immunosorbent assay for detecting Toxoplasma specific IgM antibody.

Authors:  R A Payne; D H Joynson; A H Balfour; J P Harford; D G Fleck; M Mythen; R J Saunders
Journal:  J Clin Pathol       Date:  1987-03       Impact factor: 3.411

4.  An enzyme-linked immunosorbent assay for detection of IgM antibodies to Toxoplasma gondii: use for diagnosis of acute acquired toxoplasmosis.

Authors:  Y Naot; J S Remington
Journal:  J Infect Dis       Date:  1980-11       Impact factor: 5.226

  4 in total
  5 in total

1.  Duration of toxoplasma infection.

Authors:  R E Holliman; J D Johnson
Journal:  J Clin Pathol       Date:  1991-06       Impact factor: 3.411

2.  False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test.

Authors:  O Liesenfeld; C Press; J G Montoya; R Gill; J L Isaac-Renton; K Hedman; J S Remington
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

3.  Comparison of six commercial enzyme linked immunosorbent assays for detecting IgM antibodies against Toxoplasma gondii.

Authors:  C Verhofstede; L Van Renterghem; J Plum
Journal:  J Clin Pathol       Date:  1989-12       Impact factor: 3.411

4.  Comparison of relative uses of commercial assays for Toxoplasma gondii IgM antibodies.

Authors:  D Ashburn; R Evans; L J Skinner; J M Chatterton; A W Joss; D O Ho-Yen
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

5.  [Multicenter study of toxoplasma serology using various commercial ELISA reagents. Work Group Toxoplasmosis of the National Agency for Quality Control in Parasitology].

Authors:  F Derouin; Y J Garin; C Buffard; F Berthelot; J C Petithory
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.